IP Library Granted Patent US 8,790,882
Granted Patent B2
US 8,790,882 · App. 13/934,940 · Granted Jul 29, 2014

Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Inventors: Maher Albitar (Sugar Land, TX); Michael J. Keating (Houston, TX); Taghi Manshouri (Houston, TX)
Assignee: Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,882
App. No.
13/934,940
Granted
Jul 29, 2014
Kind
B2
Abstract

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

Claims (6)

1. A method of monitoring the progress of therapy in patient being treated with a therapeutic anti-CD20 antibody, the method comprising testing a sample from the patient to measure the level of circulating cell-free CD20, circulating cell-free anti-CD20 or circulating cell-free CD20/anti-CD20 complexes.

2. The method of claim 1 , wherein the sample is selected from the group consisting of serum, cell lysate and plasma.

3. The method of claim 1 , wherein the patient is being treated with Rituximab.

4. The method of claim 1 , wherein the sample is tested to measure the level of circulating cell-free CD20.

5. The method of claim 1 , wherein the sample is tested to measure the level of circulating cell-free anti-CD20.

6. The method of claim 1 , wherein the sample is tested to measure the level of circulating cell-free CD20/anti-CD20 complexes.

Continuity (7)
Division 13543560 · Jul 6, 2012
Division 13349170 · Jan 12, 2012
Division 13080180 · Apr 5, 2011
Continuation 12761903 · Apr 16, 2010
Division 10251144 · Sep 20, 2002
Provisional Application 60323679 · Sep 20, 2001
Related Publication 20140011215A1 · Jan 9, 2014